Modality
Gene Editing
MOA
MDM2i
Target
JAK2
Pathway
Innate Imm
FTD
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Feb 2029
Phase 1Current
NCT07372533
2,436 pts·FTD
2025-04→2027-03·Not yet recruiting
NCT07187936
672 pts·FTD
2024-08→2029-02·Completed
3,108 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-1712mo awayPh2 Data· FTD
2029-02-132.9y awayPh2 Data· FTD
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P1/2
Complet…
P1/2
Not yet…
Catalysts
Ph2 Data
2027-03-17 · 12mo away
FTD
Ph2 Data
2029-02-13 · 2.9y away
FTD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07372533 | Phase 1/2 | FTD | Not yet recr... | 2436 | UPDRS |
| NCT07187936 | Phase 1/2 | FTD | Completed | 672 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |